1-(3,4-dichlorobenzyl)-2-benzimidazolinone | 147766-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(3,4-dichlorobenzyl)-2-benzimidazolinone
• 英文别名: 3-[(3,4-dichlorophenyl)methyl]-1H-benzimidazol-2-one
• CAS: 147766-00-5
• 化学式: C₁₄H₁₀Cl₂N₂O
• 分子量: 293.152
• InChiKey: MNJSQSBASMTVMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3,4-dichlorobenzyl)-2-benzimidazolinone 在 盐酸 、 sodium hydride 、 zinc(II) iodide 作用下， 以 1,4-二氧六环 为溶剂， 反应 61.09h， 生成 3-(3-(3,4-dichlorobenzyl)-2-oxo-1-benzimidazolinyl)-2-(trimethylsilyloxy)propionitrile
  参考文献：
  名称：

  Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids

  摘要：

  Potent in vitro inhibition of the enzyme aldose reductase (AR) was observed with several members of a series of 3-alkylated 2(1H)-benzimidazolone-1-acetic acids, as well as with analogs from a structurally-related series of oxindole-1-acetic acids with 3-alkyl or 3-alkylidene substituents. Intrinsic activity against AR was, in general, greatest in compounds from the second series, especially with analogs which contain alkylidene side chains, with typical IC50 values of less-than-or-equal-to 1 muM. However, in a streptozotocin-diabetic rat model, the best compounds from either series failed to prevent sorbitol accumulation in lens or sciatic nerve to the degree observed with AR inhibitors such as ponalrestat or zopolrestat.

  DOI：

  10.1016/0223-5234(92)90112-e
• 作为产物：
  描述：

  1-异丙烯基-2-苯并咪唑酮 、 3,4-二氯氯苄 在 硫酸 、 sodium hydride 、 potassium iodide 作用下， 生成 1-(3,4-dichlorobenzyl)-2-benzimidazolinone
  参考文献：
  名称：

  Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids

  摘要：

  Potent in vitro inhibition of the enzyme aldose reductase (AR) was observed with several members of a series of 3-alkylated 2(1H)-benzimidazolone-1-acetic acids, as well as with analogs from a structurally-related series of oxindole-1-acetic acids with 3-alkyl or 3-alkylidene substituents. Intrinsic activity against AR was, in general, greatest in compounds from the second series, especially with analogs which contain alkylidene side chains, with typical IC50 values of less-than-or-equal-to 1 muM. However, in a streptozotocin-diabetic rat model, the best compounds from either series failed to prevent sorbitol accumulation in lens or sciatic nerve to the degree observed with AR inhibitors such as ponalrestat or zopolrestat.

  DOI：

  10.1016/0223-5234(92)90112-e

文献信息

• [EN] PEPTIDOMIMETIC GALANIN RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS À LA GALANINE PEPTIDOMIMÉTIQUES
  申请人：ROBERTS EDWARD

  公开号：WO2012009258A2

  公开（公告）日：2012-01-19

  Potent and effective modulators of galanin receptors such as Ga1R1 and Ga1R2 are provided. Methods of preparation and methods of use are further provided. The compounds of the invention may be effective for treatment of malconditions in human patients including epilepsy or seizure disorders, mood disorders including depression and anxiety spectrum disorders; drug addiction including addiction to alcohol or tobacco; autistic spectrum diseases and pervasive development disorders; Alzheimer's disease or other dementias; cognition disorders; cerebral or myocardial stroke; demyelinating diseases including multiple sclerosis, Guillain-Barre syndrome and Charcot-Marie-Tooth disease; neurodegenerative diseases including Parkinson's disease, Lou Gehrig's diseases, Huntington's disease, and HIV dementia; neurotrauma; diabetes, obesity, metabolic syndrome and feeding disorders; solid tumors and leukemia/lymphoma; pain; neuropathies; sleeping disorders and regulation; neuroprotection; and inflammation.
• Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids
  作者：HR Howard、R Sarges、TW Siegel、TA Beyer

  DOI：10.1016/0223-5234(92)90112-e

  日期：1992.11

  Potent in vitro inhibition of the enzyme aldose reductase (AR) was observed with several members of a series of 3-alkylated 2(1H)-benzimidazolone-1-acetic acids, as well as with analogs from a structurally-related series of oxindole-1-acetic acids with 3-alkyl or 3-alkylidene substituents. Intrinsic activity against AR was, in general, greatest in compounds from the second series, especially with analogs which contain alkylidene side chains, with typical IC50 values of less-than-or-equal-to 1 muM. However, in a streptozotocin-diabetic rat model, the best compounds from either series failed to prevent sorbitol accumulation in lens or sciatic nerve to the degree observed with AR inhibitors such as ponalrestat or zopolrestat.